Search
Human cytomegalovirus immune globulin
go.drugbank.com/drugs/DB13886ApprovedInvestigationalIt contains purified immunoglobulin G (IgG) antibodies targeting cytomegalovirus (CMV)[FDA label].
Thyroid, porcine
go.drugbank.com/drugs/DB09100ApprovedInvestigational[A190813] Thyroid extracts were never FDA approved as their use in the United States predates the FDA.[A190831] … [A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891[A190807] but its use dates back as far as the 6th century.
Reslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalIL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils [FDA Label]. … Approved by the FDA in March 2016, reslizumab is marketed under the brand name Cinqair for intravenous injection. It is injected once every four weeks via intravenous infusion.
Brentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigational[L1737] Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse
Nafcillin
go.drugbank.com/drugs/DB00607ApprovedInvestigationalA semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strain...
Chlortetracycline
go.drugbank.com/drugs/DB09093ApprovedVet approvedWithdrawnChlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of...
Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigational[L34650] Obeticholic acid is currently being considered for FDA approval to treat fibrosis caused by non-alcoholic liver steatohepatitis (NASH). … [A18696,L12633] In May 2021, the FDA updated its prescribing information to contraindicate the use of obeticholic acid in patients with PBC and advanced cirrhosis (e.g. those with portal hypertension or
Miltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalThe CDC has also recommended it as a first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and granulomatous amebic encephalitis.
Zotepine
go.drugbank.com/drugs/DB09225ApprovedWithdrawn[A31857] Zotepine was never approved by the FDA. … [L1082] When the analysis of antipsychotics was retaken in 2016 by the FDA, zotepine did not reach the threshold effect to be further studied.[L1313].
Ergoloid mesylate
go.drugbank.com/drugs/DB01049Approved[L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA. … [A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued.